Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS‐CoV‐2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.70038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Allison Avrich Ciesla und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, SARS-CoV-2, Vaccine Efficacy. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: US Department of Health and Human Services, CDC HHS, Office of the National Coordinator for Health Information Technology.
Abstract (Originalsprache)
Background
On September 2, 2022, bivalent COVID‐19 mRNA vaccines, were recommended to address reduced effectiveness of COVID‐19 monovalent vaccines during SARS‐CoV‐2 Omicron variant predominance.
Methods
Using national pharmacy‐based SARS‐CoV‐2 testing program data from January 15 to September 11, 2023, this test‐negative, case–control design study assessed bivalent COVID‐19 vaccine effectiveness (VE) against symptomatic infection.
Results
VE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%–52%) for those aged ≥ 65 years to 61% (95% CI 41%–75%) for those aged 12–17 years.
Conclusion
Bivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID‐19 vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Eagle Health Analytics, San Antonio, Texas, USA.
- Office of Readiness and Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- US Public Health Service Commissioned Corps, Rockville, Maryland, USA.
ORCID-Profile: Allison Avrich Ciesla
Förderung
- US Department of Health and Human Services
- CDC HHS
- Office of the National Coordinator for Health Information Technology
- Centers for Disease Control and Prevention
Zitieren
APA
Ciesla, A. A., Mak, J., Roper, L. E., Fleming-Dutra, K. E., Smith, Z. R., Wiegand, R. E., Britton, A., Miller, J., & Link-Gelles, R. (2024). Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS‐CoV‐2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70038
Vancouver
Ciesla AA, Mak J, Roper LE, Fleming-Dutra KE, Smith ZR, Wiegand RE, et al. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS‐CoV‐2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.70038
BibTeX
@article{Ciesla2024,
author = {Ciesla, Allison Avrich and Mak, Josephine and Roper, Lauren E and Fleming-Dutra, Katherine E and Smith, Zachary R and Wiegand, Ryan E and Britton, Amadea and Miller, Joseph and Link-Gelles, Ruth},
title = {Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS‐CoV‐2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.70038}
}
EUVIMED